Department of Neurology and Neuroscience, Weil Cornell Medical College and Hospital for Special Surgery, New York, New York 10021, USA.
Curr Opin Neurol. 2012 Aug;25(4):460-5. doi: 10.1097/WCO.0b013e3283550c0d.
This review article is focused upon the most recent biomarker studies of Parkinson's disease. It provides an update on promising areas of biomarker research in a rapidly expanding field, and discusses future directions that might lead to successful development of Parkinson's disease biomarkers.
Studies of molecular-genetic and biochemical biomarkers of Parkinson's disease have not only targeted hypothesis-driven measures of specific substrates involved in processes such as protein misprocessing, but also have made use of sophisticated analyses such as transcriptomic, proteomic, and metabolomic approaches. Whereas none of these are yet established as Parkinson's disease biomarkers, brain imaging using the 123I-ioflupane ligand with single-photon emission computed tomography was recently approved in the United States to aid in Parkinson's disease diagnosis, and research on other imaging modalities is ongoing. Neurophysiological tests are also being adapted for biomarker research, and we review recent promising data.
The search for effective biomarkers for diagnosis and surveillance of Parkinson's disease continues. A battery of biomarkers comprising different modalities might be required to address clinical needs in this complex disorder. Critically, collaborative efforts including centralized tissue repository and clinical research infrastructure that are being organized will advance this field further.
本文重点介绍了帕金森病最新的生物标志物研究。综述在一个快速发展的领域中具有前景的生物标志物研究领域的最新进展，并讨论了未来可能导致成功开发帕金森病生物标志物的方向。
对帕金森病的分子遗传和生化生物标志物的研究不仅针对特定底物的假设驱动措施进行了研究，这些底物涉及蛋白质错误处理等过程，而且还利用了转录组学、蛋白质组学和代谢组学等复杂分析方法。虽然这些都尚未确立为帕金森病的生物标志物，但最近美国已经批准使用单光子发射计算机断层扫描的 123I-碘苯胍配体进行脑成像以辅助帕金森病的诊断，并且正在进行其他成像方式的研究。神经生理学测试也正在被用于生物标志物的研究，我们综述了最近有前途的研究数据。
寻找有效的帕金森病诊断和监测生物标志物的研究仍在继续。为了满足这种复杂疾病的临床需求，可能需要一系列不同模式的生物标志物组成的组合。至关重要的是，包括集中的组织库和临床研究基础设施在内的协作努力正在进一步推进这一领域的发展。
